Dyne Therapeutics (DYN) Price & Analysis

Compare

415 Followers

DYN Stock Chart & Stats

$19.59

-$0.74(-3.10%)

At close: Jan 08 4:00 PM EST

$19.59

-$0.74(-3.10%)

Day’s Range― - ―

52-Week Range$6.36 - $26.69

Previous CloseN/A

Volume117.44K

Average Volume (3M)3.11M

Market Cap

$3.17B

Enterprise Value$1.12B

Total Cash (Recent Filing)$791.89M

Total Debt (Recent Filing)$21.32M

Price to Earnings (P/E)―

Beta1.81

Next Earnings

Feb 26, 2026

EPS Estimate

-0.77

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding164,652,240

10 Day Avg. Volume4,438,740

30 Day Avg. Volume3,112,523

Financial Highlights & Ratios

PEG Ratio0.48

Price to Book (P/B)3.52

Price to Sales (P/S)0.00

P/FCF Ratio-7.53

Enterprise Value/Market Cap0.35

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.59

Forecast

1Y Price Target

$38.40

Price Target Upside96.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsDYN announced positive data from the registrational expansion cohort of DYN-251, demonstrating better results than Exondys 51 and a convenient monthly dosing.

Regulatory ApprovalManagement confirmed plans to submit for U.S. Accelerated Approval with a potential launch, positioning DYNE-251 as the clear 'chronic therapy of choice'.

Strategic AdvancesNovartis’ acquisition of Avidity has validated the strategic importance of TfR1-mediated RNA delivery platforms, making Dyne’s FORCE platform a potential next M&A candidate.

Bears Say

Program DelaysThere is a slight delay in the full enrollment of the DM1 program, now expected in early 2Q26 instead of 4Q25.

Dyne Therapeutics News

Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $36 from $38...

2d ago

DYN

Dyne Therapeutics price target raised to $39 from $36 at Stifel

Stifel raised the firm’s price target on Dyne Therapeutics (DYN) to $39 from $36 and keeps a Buy...

6d ago

DYN

Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

7d ago

Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40

As previously reported, Oppenheimer analyst Kostas Biliouris upgraded Dyne Therapeutics (DYN) to Outperform from Perform with a price...

7d ago

DYN

Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer

Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform with a $40 price target Published first on TheFly...

7d ago

DYN

Dyne Therapeutics 18.98M share Secondary priced at $18.44

The deal size was increased to $350M from $300M and priced at last closing price of $18.44. Morgan...

7d ago

DYN

Midday Fly By: Nvidia can ship H200s to China, Campbell’s reports Q1 beat

The major averages were higher near noon as traders brace for the outcome of the Federal Reserve’s upcoming...

8d ago

Dyne Therapeutics falls -13.7%

Dyne Therapeutics (DYN) is down -13.7%, or -$3.05 to $19.15. Published first on TheFly – the ultimate source...

8d ago

DYN

Dyne Therapeutics falls -13.7%

Dyne Therapeutics (DYN) is down -13.7%, or -$3.05 to $19.15. Published first on TheFly – the ultimate source...

8d ago

DYN

Dyne Therapeutics price target raised to $50 from $46 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Dyne Therapeutics (DYN) to $50 from $46 and keeps an...

8d ago

DYN

Dyne Therapeutics Announces Upsized Public Offering

An announcement from Dyne Therapeutics ( ($DYN) ) is now available. On December 9, 2025, Dyne Therapeutics announced...

6d ago

DYN

Dyne Therapeutics Amends Loan Agreement for $50 Million

Dyne Therapeutics ( ($DYN) ) has provided an update. On December 8, 2025, Dyne Therapeutics, Inc. amended its...

8d ago

DYN

Dyne Therapeutics Reports Positive Phase 1/2 Trial Results

The latest update is out from Dyne Therapeutics ( ($DYN) ). On December 8, 2025, Dyne Therapeutics announced...

9d ago

DYN

Positive Outlook for Dyne Therapeutics: Strong Financial Performance and Promising Clinical Developments Support Buy Rating

LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Dyne Therapeutics today and set a price target...

1M ago

DYN

DYN FAQ

What was Dyne Therapeutics’s price range in the past 12 months?

Dyne Therapeutics lowest stock price was $6.36 and its highest was $26.69 in the past 12 months.

What is Dyne Therapeutics’s market cap?

Dyne Therapeutics’s market cap is $3.17B.

When is Dyne Therapeutics’s upcoming earnings report date?

Dyne Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 71 days.

How were Dyne Therapeutics’s earnings last quarter?

Dyne Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.837 by $0.077.

Is Dyne Therapeutics overvalued?

According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dyne Therapeutics pay dividends?

Dyne Therapeutics does not currently pay dividends.

What is Dyne Therapeutics’s EPS estimate?

Dyne Therapeutics’s EPS estimate is -0.77.

How many shares outstanding does Dyne Therapeutics have?

Dyne Therapeutics has 164,652,240 shares outstanding.

What happened to Dyne Therapeutics’s price movement after its last earnings report?

Dyne Therapeutics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.837. Following the earnings report the stock price went down -12.919%.

Which hedge fund is a major shareholder of Dyne Therapeutics?

Currently, no hedge funds are holding shares in DYN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dyne Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-60.66%

Trailing 12-Months

Asset Growth

12.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dyne Therapeutics

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Dyne Therapeutics (DYN) Earnings & Revenues

Historic Earnings Reports

DYN Stock 12 Month Forecast

Average Price Target

$38.40

▲(96.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","34":"$34","61":"$61","20.5":"$20.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,20.5,34,47.5,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.61,23.64,26.67,29.7,32.730000000000004,35.760000000000005,38.79,41.82,44.85,47.88,50.910000000000004,53.940000000000005,56.97,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.61,21.978461538461538,23.346923076923076,24.715384615384615,26.083846153846153,27.45230769230769,28.82076923076923,30.189230769230768,31.557692307692307,32.926153846153845,34.29461538461538,35.66307692307692,37.03153846153846,{"y":38.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.61,20.33230769230769,20.054615384615385,19.776923076923076,19.49923076923077,19.22153846153846,18.943846153846152,18.666153846153847,18.388461538461538,18.11076923076923,17.833076923076923,17.555384615384614,17.27769230769231,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >